Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 625

1.

Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology.

Lasko MJ, Nicolau DP.

Curr Infect Dis Rep. 2020 Feb 7;22(3):6. doi: 10.1007/s11908-020-0716-3. Review.

PMID:
32034524
2.

'CRE, CRO, CPE and CPO': terminology past its 'sell-by-date' in an era of new antibiotics and regional carbapenemase epidemiology.

Livermore DM, Nicolau DP, Hopkins KL, Meunier D.

Clin Infect Dis. 2020 Feb 6. pii: ciaa122. doi: 10.1093/cid/ciaa122. [Epub ahead of print]

PMID:
32025698
3.

Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration.

da Costa TM, Cuba GT, Morgado PGM, Nicolau DP, Nouér SA, Dos Santos KRN, Kiffer CRV.

BMC Infect Dis. 2020 Jan 23;20(1):74. doi: 10.1186/s12879-020-4782-9.

4.

Metallo-β-lactamase resistance in Enterobacteriaceae is an artefact of currently utilized antimicrobial susceptibility testing methods.

Asempa TE, Abdelraouf K, Nicolau DP.

J Antimicrob Chemother. 2020 Jan 13. pii: dkz532. doi: 10.1093/jac/dkz532. [Epub ahead of print]

PMID:
31930305
5.

Piperacillin-Tazobactam-Resistant/Third-Generation Cephalosporin-Susceptible Escherichia coli and Klebsiella pneumoniae Isolates: Resistance Mechanisms and In vitro-In vivo Discordance.

Abdelraouf K, Chavda KD, Satlin MJ, Jenkins SG, Kreiswirth BN, Nicolau DP.

Int J Antimicrob Agents. 2020 Jan 8:105885. doi: 10.1016/j.ijantimicag.2020.105885. [Epub ahead of print]

PMID:
31923568
6.

The difficulties of identifying and treating Enterobacterales with OXA-48-like carbapenemases.

Kidd JM, Livermore DM, Nicolau DP.

Clin Microbiol Infect. 2019 Dec 31. pii: S1198-743X(19)30658-5. doi: 10.1016/j.cmi.2019.12.006. [Epub ahead of print] No abstract available.

PMID:
31899334
7.

Evaluation of the in vitro activity of WCK 5222 (cefepime/zidebactam) and currently available combination therapies against single- and double-carbapenemase producing Enterobacteriaceae: Expanding the zone of hope.

Avery LM, Mullane EM, Nicolau DP.

Int J Antimicrob Agents. 2020 Feb;55(2):105863. doi: 10.1016/j.ijantimicag.2019.105863. Epub 2019 Dec 20.

PMID:
31870597
8.

Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial.

Niederman MS, Alder J, Bassetti M, Boateng F, Cao B, Corkery K, Dhand R, Kaye KS, Lawatscheck R, McLeroth P, Nicolau DP, Wang C, Wood GC, Wunderink RG, Chastre J.

Lancet Infect Dis. 2019 Dec 19. pii: S1473-3099(19)30574-2. doi: 10.1016/S1473-3099(19)30574-2. [Epub ahead of print]

PMID:
31866328
9.

Comparative evaluation of the in vitro activities of WCK 5222 (cefepime/zidebactam) and combination antibiotic therapies against carbapenem-resistant Pseudomonas aeruginosa.

Mullane EM, Avery LM, Nicolau DP.

Antimicrob Agents Chemother. 2019 Dec 16. pii: AAC.01669-19. doi: 10.1128/AAC.01669-19. [Epub ahead of print]

PMID:
31844009
10.

Synergistic Activity of Exebacase (CF-301) in Addition to Daptomycin against Staphylococcus aureus in the Neutropenic Murine Thigh Infection Model.

Asempa TE, Abdelraouf K, Carabeo T, Schuch R, Nicolau DP.

Antimicrob Agents Chemother. 2019 Dec 9. pii: AAC.02176-19. doi: 10.1128/AAC.02176-19. [Epub ahead of print]

PMID:
31818816
11.

Meropenem-nacubactam activity against AmpC-overproducing and KPC-expressing Pseudomonas aeruginosa in a neutropenic murine lung infection model.

Asempa TE, Motos A, Abdelraouf K, Bissantz C, Zampaloni C, Nicolau DP.

Int J Antimicrob Agents. 2020 Feb;55(2):105838. doi: 10.1016/j.ijantimicag.2019.10.019. Epub 2019 Nov 6.

PMID:
31705960
12.

Falsely elevated vancomycin-concentration values from enzyme immunoassay leading to treatment failure.

Singer B, Stevens RW, Westley BP, Nicolau DP.

Am J Health Syst Pharm. 2020 Jan 1;77(1):9-13. doi: 10.1093/ajhp/zxz258.

PMID:
31697345
13.

Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation.

Kidd JM, Sakon CM, Oleksiuk LM, Cies JJ, Pettit RS, Nicolau DP, Kuti JL.

Antimicrob Agents Chemother. 2019 Dec 20;64(1). pii: e01914-19. doi: 10.1128/AAC.01914-19. Print 2019 Dec 20.

PMID:
31685468
14.

Development of Neutropenic Murine Models of Iron Overload and Depletion To Study the Efficacy of Siderophore-Antibiotic Conjugates.

Kidd JM, Abdelraouf K, Nicolau DP.

Antimicrob Agents Chemother. 2019 Dec 20;64(1). pii: e01961-19. doi: 10.1128/AAC.01961-19. Print 2019 Dec 20.

PMID:
31658967
15.

Efficacy of Humanized Cefiderocol Exposure Is Unaltered by Host Iron Overload in the Thigh Infection Model.

Kidd JM, Abdelraouf K, Nicolau DP.

Antimicrob Agents Chemother. 2019 Dec 20;64(1). pii: e01767-19. doi: 10.1128/AAC.01767-19. Print 2019 Dec 20.

PMID:
31658966
16.
17.

Single β-lactams versus combinations as empiric therapy for infections with Pseudomonas aeruginosa: assessing the in vitro susceptibility.

Almarzoky Abuhussain SS, Sutherland CA, Nicolau DP.

Infect Dis (Lond). 2020 Jan;52(1):33-38. doi: 10.1080/23744235.2019.1673900. Epub 2019 Oct 9.

PMID:
31595829
18.

Comparative In Vivo Antibacterial Activity of Human-Simulated Exposures of Cefiderocol and Ceftazidime against Stenotrophomonas maltophilia in the Murine Thigh Model.

Chen IH, Kidd JM, Abdelraouf K, Nicolau DP.

Antimicrob Agents Chemother. 2019 Oct 7. pii: AAC.01558-19. doi: 10.1128/AAC.01558-19. [Epub ahead of print]

PMID:
31591126
19.

Pharmacologic optimization of antibiotics for Gram-negative infections.

Gill CM, Nicolau DP.

Curr Opin Infect Dis. 2019 Dec;32(6):647-655. doi: 10.1097/QCO.0000000000000601.

PMID:
31567737
20.
21.

Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.

Avery LM, Chen IH, Reyes S, Nicolau DP, Kuti JL.

Clin Ther. 2019 Oct;41(10):2162-2170. doi: 10.1016/j.clinthera.2019.08.005. Epub 2019 Sep 7.

PMID:
31506218
22.

Development of Daptomycin Susceptibility Breakpoints for Enterococcus faecium and Revision of the Breakpoints for other Enterococcal species by the Clinical and Laboratory Standards Institute.

Satlin MJ, Nicolau DP, Humphries RM, Kuti JL, Campeau SA, Lewis JS, Weinstein MP, Jorgensen JH; CLSI Subcommittee on Antimicrobial Susceptibility Testing and Ad Hoc Working Group on Revision of Daptomycin Enterococcal Breakpoints.

Clin Infect Dis. 2019 Aug 26. pii: ciz845. doi: 10.1093/cid/ciz845. [Epub ahead of print]

PMID:
31504338
23.

Monte Carlo Simulation Methodologies for β-Lactam/β-Lactamase Inhibitor Combinations: Effect on Probability of Target Attainment Assessments.

Kidd JM, Stein GE, Nicolau DP, Kuti JL.

J Clin Pharmacol. 2020 Feb;60(2):172-180. doi: 10.1002/jcph.1510. Epub 2019 Aug 18.

PMID:
31423601
24.

Use of continuous infusion ceftolozane-tazobactam with therapeutic drug monitoring in a patient with cystic fibrosis.

Elizabeth Davis S, Ham J, Hucks J, Gould A, Foster R, Ann Justo J, Nicolau DP, Bookstaver PB.

Am J Health Syst Pharm. 2019 Apr 8;76(8):501-504. doi: 10.1093/ajhp/zxz011.

PMID:
31361864
25.

Application of the Hartford Hospital Nomogram for Plazomicin Dosing Interval Selection in Patients with Complicated Urinary Tract Infection.

Asempa TE, Kuti JL, Seroogy JD, Komirenko AS, Nicolau DP.

Antimicrob Agents Chemother. 2019 Sep 23;63(10). pii: e00148-19. doi: 10.1128/AAC.00148-19. Print 2019 Oct.

PMID:
31358580
26.

Recovery of Gram-Negative Bacteria from Aerobic Blood Culture Bottles Containing Antibiotic Binding Resins after Exposure to β-Lactam and Fluoroquinolone Concentrations.

Chen IH, Nicolau DP, Kuti JL.

J Clin Microbiol. 2019 Sep 24;57(10). pii: e00849-19. doi: 10.1128/JCM.00849-19. Print 2019 Oct.

PMID:
31340990
27.

Pharmacokinetics-pharmacodynamics of β-lactamase inhibitors: are we missing the target?

Monogue ML, Nicolau DP.

Expert Rev Anti Infect Ther. 2019 Aug;17(8):571-582. doi: 10.1080/14787210.2019.1647781. Epub 2019 Jul 30.

PMID:
31340665
28.

Comparative efficacy of linezolid and vancomycin for endotracheal tube MRSA biofilms from ICU patients.

Fernández-Barat L, Motos A, Panigada M, Álvarez-Lerma F, Viña L, Lopez-Aladid R, Ceccato A, Bassi GL, Nicolau DP, Lopez Y, Muñoz L, Guerrero L, Soy D, Israel T, Castro P, Torres A.

Crit Care. 2019 Jul 10;23(1):251. doi: 10.1186/s13054-019-2523-5.

29.

In vitro potency of antipseudomonal β-lactams against blood and respiratory isolates of P. aeruginosa collected from US hospitals.

Almarzoky Abuhussain SS, Sutherland CA, Nicolau DP.

J Thorac Dis. 2019 May;11(5):1896-1902. doi: 10.21037/jtd.2019.05.13.

30.

Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia.

Avery LM, Kuti JL, Weisser M, Egli A, Rybak MJ, Zasowski EJ, Arias CA, Contreras GA, Chong PP, Aitken SL, DiPippo AJ, Wang JT, Britt NS, Nicolau DP.

Int J Antimicrob Agents. 2019 Sep;54(3):346-350. doi: 10.1016/j.ijantimicag.2019.07.002. Epub 2019 Jul 5.

PMID:
31284042
31.

In Vitro Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against Pseudomonas aeruginosa.

Asempa TE, Nicolau DP, Kuti JL.

Antimicrob Agents Chemother. 2019 Aug 23;63(9). pii: e00997-19. doi: 10.1128/AAC.00997-19. Print 2019 Sep.

PMID:
31262769
33.

A Simulated Application of the Hartford Hospital Aminoglycoside Dosing Nomogram for Plazomicin Dosing Interval Selection in Patients With Serious Infections Caused by Carbapenem-Resistant Enterobacterales.

Asempa TE, Kuti JL, Seroogy JD, Komirenko AS, Nicolau DP.

Clin Ther. 2019 Aug;41(8):1453-1462. doi: 10.1016/j.clinthera.2019.04.038. Epub 2019 Jun 24.

PMID:
31248681
34.

Ceftolozane-Tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Mechanisms of Resistance.

Petraitis V, Petraitiene R, Naing E, Aung T, Thi WP, Kavaliauskas P, Win Maung BB, Michel AO, Ricart Arbona RJ, DeRyke AC, Culshaw DL, Nicolau DP, Satlin MJ, Walsh TJ.

Antimicrob Agents Chemother. 2019 Aug 23;63(9). pii: e00344-19. doi: 10.1128/AAC.00344-19. Print 2019 Sep.

PMID:
31235620
35.

In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model.

Monogue ML, Tabor-Rennie J, Abdelraouf K, Nicolau DP.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00233-19. doi: 10.1128/AAC.00233-19. Print 2019 Jul.

36.

In vitro investigation of synergy among fosfomycin and parenteral antimicrobials against carbapenemase-producing Enterobacteriaceae.

Avery LM, Sutherland CA, Nicolau DP.

Diagn Microbiol Infect Dis. 2019 Oct;95(2):216-220. doi: 10.1016/j.diagmicrobio.2019.05.014. Epub 2019 May 25.

PMID:
31213392
37.

Carbapenem-Nonsusceptible Pseudomonas aeruginosa Isolates from Intensive Care Units in the United States: a Potential Role for New β-Lactam Combination Agents.

Asempa TE, Nicolau DP, Kuti JL.

J Clin Microbiol. 2019 Jul 26;57(8). pii: e00535-19. doi: 10.1128/JCM.00535-19. Print 2019 Aug.

38.

In Vivo Pharmacodynamic Profile of Ceftibuten-Clavulanate Combination against Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in the Murine Thigh Infection Model.

Abdelraouf K, Stainton SM, Nicolau DP.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00145-19. doi: 10.1128/AAC.00145-19. Print 2019 Jul.

39.

In Vitro Pharmacodynamics of a Novel Ceftibuten-Clavulanate Combination Antibiotic against Enterobacteriaceae.

Grupper M, Stainton SM, Nicolau DP, Kuti JL.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00144-19. doi: 10.1128/AAC.00144-19. Print 2019 Jul.

40.

In vitro activity of ampicillin and ceftriaxone against ampicillin-susceptible Enterococcus faecium.

Lorenzo MP, Kidd JM, Jenkins SG, Nicolau DP, Housman ST.

J Antimicrob Chemother. 2019 Aug 1;74(8):2269-2273. doi: 10.1093/jac/dkz173.

PMID:
31050740
41.

Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosa.

Avery LM, Sutherland CA, Nicolau DP.

J Med Microbiol. 2019 Jun;68(6):893-897. doi: 10.1099/jmm.0.000984. Epub 2019 May 3.

PMID:
31050629
42.

Pharmacokinetics of Cefazolin and Vancomycin in Infants Undergoing Open-Heart Surgery With Cardiopulmonary Bypass.

Ingrande J, Gutierrez K, Lemmens HJ, Verma A, Nicolau DP, Sutherland CA, Ramamoorthy C.

Anesth Analg. 2019 May;128(5):935-943. doi: 10.1213/ANE.0000000000003876.

PMID:
30995208
43.

Nebulized Amikacin and Fosfomycin for Severe Pseudomonas aeruginosa Pneumonia: An Experimental Study.

Li Bassi G, Motos A, Fernandez-Barat L, Aguilera Xiol E, Chiurazzi C, Senussi T, Saco MA, Fuster C, Carbonara M, Bobi J, Amaro R, De Rosa F, Comaru T, Yang H, Ranzani OT, Marti JD, Rinaudo M, Comino Trinidad O, Rigol M, Bringué J, Ramirez J, Nicolau DP, Pelosi P, Antonelli M, Blasi F, Artigas A, Montgomery AB, Torres A.

Crit Care Med. 2019 Jun;47(6):e470-e477. doi: 10.1097/CCM.0000000000003724.

PMID:
30882478
44.

Where should antibiotic gradient diffusion strips be crossed to assess synergy? A comparison of the standard method with a novel method using steady-state antimicrobial concentrations.

Motos A, Avery LM, DeRonde KJ, Mullane EM, Kuti JL, Nicolau DP.

Int J Antimicrob Agents. 2019 May;53(5):698-702. doi: 10.1016/j.ijantimicag.2019.03.006. Epub 2019 Mar 14.

PMID:
30880231
45.

Reply to Cheng and Chuang.

Avery LM, Kuti JL, Weisser M, Egli A, Rybak MJ, Zasowski EJ, Arias CA, Contreras GA, Chong PP, Aitken SL, DiPippo AJ, Wang JT, Britt NS, Nicolau DP.

Clin Infect Dis. 2019 Aug 16;69(5):903-904. doi: 10.1093/cid/ciz081. No abstract available.

PMID:
30715199
46.

Efficacy of Human-Simulated Epithelial Lining Fluid Exposure of Meropenem-Nacubactam Combination against Class A Serine β-Lactamase-Producing Enterobacteriaceae in the Neutropenic Murine Lung Infection Model.

Asempa TE, Motos A, Abdelraouf K, Bissantz C, Zampaloni C, Nicolau DP.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02382-18. doi: 10.1128/AAC.02382-18. Print 2019 Apr.

47.

Development of an HPLC-MS/MS method for the determination of ceftolozane/tazobactam in bronchoalveolar lavage fluid.

Sutherland CA, Ozbal C, Nicolau DP.

Future Sci OA. 2018 Nov 15;5(1):FSO352. doi: 10.4155/fsoa-2018-0079. eCollection 2019 Jan.

48.

Epidemiology of Bloodstream Infections Caused by Escherichia coli and Klebsiella pneumoniae That Are Piperacillin-Tazobactam-Nonsusceptible but Ceftriaxone-Susceptible.

Baker TM, Rogers W, Chavda KD, Westblade LF, Jenkins SG, Nicolau DP, Kreiswirth BN, Calfee DP, Satlin MJ.

Open Forum Infect Dis. 2018 Nov 19;5(12):ofy300. doi: 10.1093/ofid/ofy300. eCollection 2018 Dec.

49.
50.

Patient preferences for treatment of acute bacterial skin and skin structure infections in the emergency department.

Almarzoky Abuhussain SS, Burak MA, Kohman KN, Jacknin G, Tart SB, Hobbs ALV, Adams DK, Nailor MD, Keyloun KR, Nicolau DP, Kuti JL.

BMC Health Serv Res. 2018 Dec 4;18(1):932. doi: 10.1186/s12913-018-3751-0.

Supplemental Content

Loading ...
Support Center